GO
Loading...

Actavis Inc

More

  • BOSTON, Nov 26- Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.. One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker's biggest...

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • CEOs in 10 big mergers to get $430M: Study Friday, 21 Nov 2014 | 8:20 AM ET
    David Pyott

    CEOs who decided to sell in the 10 biggest U.S. deals this year will rake in $430 million in "golden parachute" payments, according to a study.

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.

  • Family gets $6.75 million in Botox treatment case Thursday, 20 Nov 2014 | 3:41 PM ET

    The verdict, in U.S. District Court in Burlington, came three days after the announcement that Parsippany, New Jersey- based drugmaker Actavis would acquire Botox maker Allergan for $66 billion, one of the biggest acquisitions announced this year. Thursday's verdict came four years after Irvine, California- based Allergan agreed to pay $600 million, pleading...

  • Nov 20- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc was trumped by Actavis Plc's $66...

  • *Nikkei erases gains, Asia shares hit by weak commodity prices. TOKYO, Nov 19- Japanese shares gave up early gains on Wednesday as investors booked profits after Prime Minister Shinzo Abe delayed a tax hike and said he would call a snap election to seek a fresh mandate for his economic policies. Japan's Nikkei erased earlier gains to stand flat by midday, showing...

  • TOKYO, Nov 19- Japanese stocks rose on Wednesday as investors held out hope for more robust growth after Prime Minister Shinzo Abe delayed a tax hike and called an early election to seek a fresh mandate for his aggressive policies to shore up the economy. MSCI's broadest index of Asia-Pacific shares outside Japan was a touch lower while Japan's Nikkei rose 0.6...

  • NYSE stocks posting largest volume increases Tuesday, 18 Nov 2014 | 6:03 PM ET

    NEW YORK— A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:. Actavis plc: Approximately 12,976,600 shares changed hands, a 442.1 percent increase over its 65- day average volume. The shares rose $21.66 or 8.7 percent to $269.60.

  • Actavis Plc, Gilead Sciences and other biotechs were among the biggest drivers, a day after Allergan agreed to be bought by Actavis. Shares of Actavis were up 8.7 percent at $269.60, helped by bullish analyst notes, while Gilead's stock rose 3.3 percent to $103.71 percent. "A little bit of a risk trade is coming back on, and those are the areas for the M&A," said Uri...

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • NYSE stocks posting largest percentage increases Tuesday, 18 Nov 2014 | 1:25 PM ET

    NEW YORK— A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:. SunEdison Inc. rose 29.3 percent to $21.48. Seabridge Gold Inc. rose 8.9 percent to $7.96.

  • US STOCKS-S&P 500 hits record again; Actavis rallies Tuesday, 18 Nov 2014 | 11:01 AM ET

    NEW YORK, Nov 18- U.S. stocks rose on Tuesday, lifting the S&P 500 to a record high, boosted by healthcare after Actavis' acquisition of Allergan triggered bullish analyst notes. Allergan on Monday accepted a $66 billion takeover bid from Actavis Plc in cash and stock. At least two analysts raised Actavis' price target, one to as high as $300.

  • Asia stocks down as China property, Japan weighed Tuesday, 18 Nov 2014 | 12:31 AM ET

    A positive outlook from homebuilders and encouraging news from Japan and Germany also helped lift markets. "We've gotten good news on all of the worries since mid-October and we had much better-than-expected earnings," said Kate Warne, an investment strategist at Edward Jones. Developments in Japan, whose economy slipped into recession in the third quarter,...

  • A day after shock data showing Japan slipping into recession had rattled financial markets, Japan's Nikkei rose 1.7 percent, erasing about a half of Monday's 3.0 percent fall. Prime Minister Shinzo Abe is expected to announce later in the day that he is calling a snap election, banking on the ruling Liberal Democrat Party trouncing a weak opposition to reaffirm...

  • NYSE stocks posting largest volume increases Monday, 17 Nov 2014 | 6:02 PM ET

    NEW YORK— A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:. Actavis plc: Approximately 15,691,000 shares changed hands, a 624.3 percent increase over its 65- day average volume. The shares rose $4.17 or 1.7 percent to $247.94.

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...